

In Vitro Antifungal Susceptibility Profiles of *Candida albicans* Complex Isolated from Patients with Respiratory Infections

Somayeh Sharifynia¹, Hamid Badali², Mina Sharifi Sorkherizi¹, Mohammad Reza Shidfar¹, Atefe Hadian¹, Shadi Shahrokhi³, Ghazale Ghandchi⁴, and Sassan Rezaie¹

¹Department of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

²Department of Medical Mycology and Parasitology, Pharmaceutical Sciences Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

³Islamic Azad University, Varamin-Pishva Branch, Varamin, Iran

⁴Pediatric Infections Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Received: 04 Jun. 2015; Accepted: 6 Dec. 2015

Abstract- *Candidiasis*, the main opportunistic fungal infection has been increased over the past decades. This study aimed to characterize *C. albicans* species complex (*C. albicans*, *C. dubliniensis*, and *C. africana*) isolated from patients with respiratory infections by molecular tools and *in vitro* antifungal susceptibilities by using broth microdilution method according to CLSI M27-A3 guidelines. Totally, 121 respiratory samples were collected from patients with respiratory infections. Of these, 83 strains were germ tube positive and green colonies on chromogenic media, so initially identified as *C. albicans* species complex and subsequently were classified as *C. albicans* (89.15%), *C. dubliniensis* (9.63%), and *C. africana* (1.2%) based on PCR-RFLP and amplification of *hwp1* gene. Minimum inhibitory concentration (MICs) results showed that all tested isolates of *C. albicans* complex were highly susceptible to triazole drugs. However, caspofungin had highest activity against *C. albicans*, *C. dubliniensis*, and *C. africana*. Our findings indicated the variety of antifungal resistance of *Candida* strains in different areas. These results may increase the knowledge about the local distribution of the mentioned strains as well as their antifungal susceptibility pattern which play an important role in appropriate therapy.

© 2016 Tehran University of Medical Sciences. All rights reserved.

Acta Med Iran, 2016;54(6):376-381.

Keywords: *In vitro* susceptibility; *C. albicans* complex; Caspofungin

Introduction

Candidiasis is the main opportunistic fungal infection which has been increased over the past decades (1). Invasive infection caused by *Candida* species are associated with high mortality ranging from 40% to 60% (2). Disseminated *Candidiasis* mainly involves the lungs. The autopsies from patients with disseminated *Candidiasis* have shown the pulmonary involvement in half of these patients which has considerable mortality (3).

C. albicans is a commensal and a constituent in the mucosa of healthy individuals. It's also the most common opportunistic human fungal pathogen. In the majority of epidemiological studies has been found to be the most common cause of superficial and systemic fatal infections in immunocompromised or critically ill

patients. It is recognized as the fourth leading cause of nosocomial infections (4,5). Moreover, *C. dubliniensis* is closely related to *C. albicans* and shares many phenotypic properties traits with *C. albicans* such as the ability to form chlamydo spores and germ tubes. However, it is often quite difficult to discriminate between the two species in clinical samples (5,6). Differences between these two species were most pronounced at the genetic variation and seemed to be important in medical mycology, *C. dubliniensis* exhibits increased adherence to epithelial cells and may have a higher propensity to develop azole antifungal drug resistance rather than *C. albicans* (7). Atypical *C. albicans* strains, i.e., *C. africana* have been reported in vaginitis, from African, German, Spanish, and Italian patients who considered an atypical chlamydo spores-negative *C. albicans* strain (8). Based on molecular

Corresponding Author: S. Rezaie

Department of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Tel: +98 21 88951392, Fax: +98 21 66462267, E-mail address: srezaie@tums.ac.ir

studies *C. africana* cannot be yet considered as a new species of *Candida*. These data suggest that *C. albicans* var. *africana* is a more suitable name for these atypical *C. albicans* strains (9). Epidemiology, virulence, and antifungal and intrinsic susceptibility pattern often vary among strains. Therefore a rapid and accurate identification of the species causing disease is crucial for primary antifungal regimens that be adjusted to the local epidemiological studies.

In the present study, we used a PCR-based molecular method for discriminating between *C. albicans*, *C. africana*, and *C. dubliniensis* by performing a single pair of primers targeting the *hwp1* gene. For this aim, we used *C. albicans* complex strains which isolated from patients with respiratory infection symptoms and identified by phenotypic and molecular methods. Antifungal susceptibility testing was conducted according to clinical and laboratory standard institute (CLSI) document M27-A3.

Materials and Methods

This study was performed in the Division of Molecular Biology, Department of Medical Mycology and Parasitology, Tehran University of Medical Sciences. Totally, 121 respiratory samples including sputum and broncho alveolar lavage (BAL) samples obtained from patients with respiratory infection symptoms. Among these samples, 83 strains were identified as *C. albicans* complex based on phenotypic methods (colony color on *Candida* Chrome agar medium (CHOROM agar Company, Paris, France) and germ-tube formation in serum at 37°C). Subsequently, confirmations were performed based on PCR-RFLP method. Briefly, genomic DNA was extracted using glass beads and the phenol/chloroform method and stored at -20°C prior to use (3,10). The contiguous ITS1-5.8S rDNA-ITS2 region was amplified by using PCR mixture containing 5 µl of 10x reaction buffer, 1.5 mM MgCl₂, 0.4 mM dNTPs, 0.5 U of DNA Taq polymerase, 10 pmol of each ITS1 (5' -TCC GTA GGT GAA CCT GCG G-3') and ITS4 (5' -TCC TCC GCT TAT TGA TAT GC-3') primers, and 2 µl of extracted DNA in a final volume of 25 µl. The amplification parameters consist of 35 cycles. The PCR condition was an initial denaturation at 94°C for 5 min, second denaturation at 94°C for 30 s, annealing at 56°C for 45 s, and extension at 72°C for 1 min and 15 s, with a final extension step at 72°C for 8 min. The products resulting were visualized by ethidium bromide in 1% agarose gel electrophoresis. The restriction fragment was then obtained by digestion

of 5 µl PCR products with 0.5 µl of restriction enzyme *Msp I* (Fermentas, Vilnius, Lithuania) at 1.5 µl Tango buffer and 8 µl Molecular grade water in 37°C for 2 h. Restriction fragments were separated on a 2% agarose gel in TAE buffer for 1.45 h at 100 V. The size of DNA fragments determined directly with a comparison of molecular size marker and distinct banding patterns which demonstrated in previous studies. The size of banding pattern for ITS PCR product (537 bp) and its fragments digested by *Msp I* (239 and 298 bp) was mentioned previously in *C. albicans* complex (10). The validated *C. albicans* strains were then used for further study concerning differentiation from *C. dubliniensis* as well as *C. africana*. Then, definite identification of *C. albicans*, *C. dubliniensis* and *C. africana* were performed by PCR amplification of the hyphal wall protein1 (*hwp1*) gene by using the forward 5'GCTACCACTTCAGAATCATCATC-3' and reverse 5' GCACCTTCAGTCGTAGAGACG-3' primer pairs. Briefly, PCR reaction conditions were as follows: denaturation at 95 °C for 5 min, 30 cycles of denaturation at 94 °C for 45 s, primer annealing at 58 °C for 40 s, and extension at 72 °C for 55 s, followed by a final extension at 72 °C for 10 min. PCR products were separated on a 1% (wt/vol) agarose gel. *C. albicans* isolates, including the reference showed the expected DNA fragment (~1000 bp), *C. dubliniensis* strains produced a fragment of (569 bp) and *C. africana* (~700 bp) (8).

In vitro antifungal susceptibility testing was performed for 83 identified strains by broth microdilution method according to the clinical and laboratory standard institute (CLSI) document M27-A3. MICs (minimum inhibitory concentrations) of four antifungal drugs; fluconazole (Pfizer Central Research, Sandwich, United Kingdom), itraconazole (Janssen Research Foundation, Beerse, Belgium), caspofungin (CAS, MerckSharp & Dohme, Haarlem, The Netherlands), and amphotericin B (AMB, Bristol-Myers Squib, Woerden, The Netherlands) were evaluated. Stock solutions of the drugs were prepared in the appropriate solvent according to the CLSI. The targeted final concentrations were for fluconazole (0.063-64 µg/ml), for caspofungin (0.008-8 µg/ml) and for amphotericin B and itraconazole (0.16-16 µg/ml). Aliquot in 96 well microdilution plates and store at -70°C until used. Final inoculum suspensions were prepared from 24 hr of *C. albicans* complex cultures ranged from 0.5×10^3 to 2.5×10^3 CFU/ml by spectrophotometr. The plates were then incubated at 35°C for 48 hr. Visual readings were performed with the

Antifungal susceptibility of *Candida albicans* complex in vitro

help of a mirror. The MICs endpoints of fluconazole have been defined as the level which induced a prominent reduction of growth (50% inhibition compared to drug-free growth control). Visible fungal growth which can be inhibited 100% is considered as MIC for amphotericin B, itraconazole and caspofungin. *In vitro* susceptibilities were then evaluated according to the currently established interpretation criteria of the CLSI. For fluconazole, strains are considered as susceptible when the MIC \leq 8 μ g/ml, susceptible dose dependent MIC=16-32 μ g/ml, and resistant with MIC \geq 64 μ g/ml. Corresponding criteria for itraconazole MIC \leq 0.125 μ g/ml is susceptible, MIC=0.25-0.5 μ g/ml dose dependent and MIC \geq 1 μ g/ml is resistant. Amphotericin B considered as resistant with \geq 2 μ g/ml and susceptible in $<$ 1 μ g/ml MICs. For caspofungin, the fungal growth is considered as susceptible and resistant

when MIC $<$ 2 μ g/ ml and MIC $>$ 2 μ g/ ml, respectively (11-13). *Candida parapsilosis* (ATCC 22019) was chosen as quality controls to be used with every new series of MICs plates.

Results

From all tested isolates that initially identified as *C.albicans* complex, 89.15%, 9.63%, 1.2% was identified as *C.albicans*, *C. dubliniensis*, and *C. africana* respectively, by amplification of the *hwp1* gene (Figure 1). *Candida albicans* was the dominant *Candida* species (n=74; 89.15 %) obtained from respiratory samples. The comparative *in vitro* susceptibilities of the *C.albicans* complex isolated from patients with respiratory infection symptoms against antifungal agents summarized in Table 1.

Table 1. The comparative *in vitro* susceptibilities of the *Candida albicans* complex strains isolated from patients with respiratory infection symptom to antifungal agents

Species n (%)	Antifungal	MIC ₅₀	MIC ₉₀	Range	Susceptible n (%)	Resistance n (%)	Dose Dependent n (%)
<i>C.albicans</i> 89.15%(74)	fluconazole	1	32	0.125-64	56(75.67)	14 (18.91)	4 (5.4)
	itraconazole	0.125	16	0.016-16	43(58.1)	19 (25.67)	12 (16.21)
	caspofungin	0.125	0.5	0.008-8	73(98.64)	1 (1.53)	--
	amphotericin B	2	8	0.016-16	28(37.83)	46 (62.16)	--
<i>C. dubliniensis</i> 9.63%(8)	fluconazole	1	ND	0.5-64	3(37.5)	4 (50)	1 (12.5)
	itraconazole	0.125	ND	0.016-16	3(37.5)	4 (50)	1 (12.5)
	caspofungin	0.25	ND	0.016-1	(100)	--	--
	amphotericin B	2	ND	0.25-4	3(37.5)	5 (62.5)	--
<i>C. africana</i> 1.2%(1)	fluconazole	ND	ND	0.5	1(100)	--	--
	itraconazole	ND	ND	0.016	1(100)	--	--
	caspofungin	ND	ND	0.008	1(100)	--	--
	amphotericin B	ND	ND	8	--	1 (100)	--

ND: not determined

Overall 18.91 % (n=14) of *C.albicans* isolates and 50 % (n=4) of *C. dubliniensis* were resistance to fluconazole (MIC \geq 64 μ g/ ml). 25.67% (n=19) and 50 % (n=4) of *C.albicans* and *C. dubliniensis* were resistance to itraconazole respectively (MIC \geq 1 μ g/ ml). For caspofungin, 1.53% (n=1) of *C.albicans* strain was resistant (MIC \geq 2 μ g/ ml), and *C. dubliniensis* was susceptible at MIC \leq 2 μ g/ ml. Our data were shown, 62.16 % (46) and 62.5 % (5) of *C.albicans* and *C. dubliniensis* were resistance to amphotricin B (MIC \geq 2 μ g/ ml). *C.africana* was susceptible to fluconazole (MIC=0.5 μ g/ml), itraconazole (MIC=0.016 μ g/ml), Caspofungin (MIC=0.008 μ g/ml), whereas resistance to amphotricin B (MIC=8 μ g/ml).

Also our results indicated that, 5.4% (n=4) and 12.5 % (n=1) of *C. albicans* and *C.dubliniensis* were dose-

dependent to fluconazole respectively (MIC=16-32 μ g/ ml), whereas 16.21 % (12) and 12.5 % (1) of these isolates were dose-dependent to itraconazole respectively (MIC=0.25–0.5 μ g/ml). Table 1 summarizes the results of MIC₅₀ and MIC₉₀; *C.albicans* showed higher MIC₅₀ (2 μ g/ml) with amphotericin B compared to caspofungin and azole tested agents. However, caspofungin demonstrated the lowest MIC₅₀ (0.25 μ g/ml) against *C.dubliniensis*. In addition, *C.africana* was fully susceptible to fluconazole (MIC=0.5 μ g/ml), Itraconazole (MIC=0.016 μ g/ml), and caspofungin (MIC=0.008 μ g/ml).

Results revealed, 8.91% of *C.albicans* were resistance to fluconazole and itraconazole. Besides, 16.2% of these isolates showed resistance to fluconazole, itraconazole, and amphotericin B.




Figure 1. Species-specific amplification of the *hwp1* gene; *C. dubliniensis* (569 bp) (lines:1,2), *C. albicans* (~1000 bp) (lines:3,4), and *C. africana* (~700 bp) (lines:5,6), using *hwp1* gene.

Discussion

C. albicans is the most common cause of invasive fungal infections and represents a serious public health challenge due to increasing medical and economic importance (14-16). However, *C. dubliniensis* emerging as a pathogen and has frequently been misidentified as *C. albicans* by clinical laboratories (7). In addition, *C. africana* which has been considered as a pathogen and reported as an atypical *C. albicans*, was isolated from patients suffered from vaginitis in several regions (8). Rapid identification of the mentioned strains seems to be crucial due to possible antifungal susceptibility as well as local epidemiological studies. In this investigation, the species that initially have been identified as *C. albicans* complex were further identified as *C. albicans* (89.15%), *C. dubliniensis* (9.63%), and *C. africana* (1.2%) by amplification of *hwp1* gene. Our results were different from the data reported by Bosco-Borgeat *et al.*, in which the rate of *C. dubliniensis* from fungemia was indicated as 0.96% (7). In addition, Moran *et al.*, have reported this rate as 2-3% of cases (5). Our obtained results shows the rate of *C. africana* to be 1.2% (n=1) among all isolates, however this result was incompatible to the results of Romeo *et al.*, in which the mentioned rate was reported as 7.2% with the same method. The obtained antifungal susceptibility results indicated that *C. albicans* isolates from patients with respiratory infection symptoms were highly susceptible to caspofungin (98.64%) ($MIC_{90} \leq 0.5$ $\mu\text{g/ml}$). This findings are in agreements with Lemos *et al.*, and Kumar *et al.*, (1,17). Resistance to the echinocandins was reported previously to be distinctly rare (overall range, 0.0 to 1.2%) among *C. albicans* (18,19). In this investigation 18.91% of *C. albicans* strains were highly resistance to fluconazole ($MIC \geq 64$ $\mu\text{g/ml}$). We also found that fluconazole had the widest

range (0.0063-64) and the highest MICs in *C. albicans*, whereas other studies like Wiebusch *et al.*, Wabe *et al.*, Njunda *et al.*, Shokohi *et al.*, Roy *et al.*, reported the rates of this resistance as 45.83%, 11.9%, 74.2%, 2.7%, 38.7% respectively (11,20-23). The difference in fluconazole resistance between our result and the same from Shokohi *et al.*, may be due to differences in investigated populations, as well as rare prescription of fluconazole to the most cancer patients as a standard care in Iran. Therefore, data exhibit a high prevalence of fluconazole resistance among *Candida* species may be correlated with the increased use of fluconazole in area of study. Other data reported by; Shokohi *et al.*, Almamari *et al.*, Aher *et al.*, Awari *et al.*, and Royet *et al.*, indicated the resistance of *C. albicans* to itraconazole as 5.4%, 10.3%, 36.9%, 35% and 19.3% respectively (20,24-26). However, 18.91% of *C. albicans* strains were shown to be fully resistant to both; itraconazole and fluconazole.

In addition, 62.16% of *C. albicans* isolates in our study were indicated to be resistant to amphotericin B. The latter result was similar to the result reported by Njunda *et al.*, (54.4%), and differ from the results of Aher *et al.*, (13.8%), Awari *et al.*, (7.5%) Roy *et al.*, (0%), and Bosco-Borgeat *et al.*, (0%) (7,21,23,25-27). Obtained MIC Range (0.016-16) and MIC_{90} (8) for amphotericin B in present study differ from the data of Bosco-Borgeat *et al.*, which reported MIC Range and MIC_{90} as (0.13-1 $\mu\text{g/ml}$) and (0.5) respectively (7). Besides, the rates 50%, 62.5%, and 62.5% of *C. dubliniensis* strains were resistance to fluconazole, itraconazole, and amphotericin B respectively. However, 100% of strains were susceptible to caspofungin. Compared with the results of Bosco-Borgeat *et al.*, our result showed lower susceptibility of fluconazole and itraconazole in *C. albicans* and *C. dubliniensis* strains. Such incompatibility is also observed with the results of Zhang *et al.*, that reports the resistance to fluconazole in 20% of *C. dubliniensis* (27). According to our data, *C. africana* was susceptible to fluconazole, itraconazole, caspofungin and resistance to amphotericin B. Caspofungin demonstrated the highest activity against *C. albicans*, *C. dubliniensis* and *C. africana*. Therefore caspofungin seems to be the most active drug for pulmonary and disseminated candidiasis treatment (28). In conclusion, this study revealed, antifungal susceptibility pattern in *C. albicans*, *C. dubliniensis* and *C. africana* derived from clinical samples of patient with respiratory infection symptoms. Such a local surveillance studies is required for control the spread of resistance which would be helpful to develop effective

treatment strategies, prophylaxis and antifungal susceptibility pattern of different *Candida* strains that seems to be important for appropriate therapy.

Acknowledgment

This study was financially supported by a grant from the School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, which we gratefully acknowledge. We are grateful to M.R. Safari for excellent technical assistance.

References

1. Lemos JdA, Costa CR, Araújo CRd, Hasimoto e Souza LK, Silva MdRR. Susceptibility testing of *Candida albicans* isolated from oropharyngeal mucosa of HIV+ patients to fluconazole, amphotericin B and Caspofungin: killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates. *Braz J Microbiol* 2009;40:163-9.
2. Storm L, Lausch KR, Arendrup MC, Mortensen KL, Petersen E. Vertebral infection with *Candida albicans* failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine. *Med Mycol Case Rep* 2014;6:6-9.
3. Afsarian MH, Badali H, Boekhout T, Shokohi T, Katirae F. Multilocus sequence typing of *Candida albicans* isolates from a burn intensive care unit in Iran. *J Med Microbiol* 2015;64:248-53.
4. Bai FY. Association of genotypes with infection types and antifungal susceptibilities in *Candida albicans* as revealed by recent molecular typing strategies. *Mycology* 2014;5:1-9.
5. Moran GP, Coleman DC, Sullivan DJ. *Candida albicans* versus *Candida dubliniensis*: why is *C.albicans* more pathogenic? *Int J Microbiol.* 2012;2012:205921.
6. Ahmad S, Khan Z, Asadzadeh M, Theyyathel A, Chandy R. Performance comparison of phenotypic and molecular methods for detection and differentiation of *Candida albicans* and *Candida dubliniensis*. *BMC Infect Dis* 2012;12:230.
7. Bosco-Borgeat ME, Taverna CG, Cordoba S, Isla MG, Murisengo OA, Szusz W, et al. Prevalence of *Candida dubliniensis* fungemia in Argentina: identification by a novel multiplex PCR and comparison of different phenotypic methods. *Mycopathologia* 2011;172:407-14.
8. Romeo O, Criseo G. First molecular method for discriminating between *Candida Africana*, *Candida albicans*, and *Candida dubliniensis* by using hwp1 gene. *Diagn Microbiol Infect Dis* 2008;62:230-3.
9. Romeo O, Criseo G. Molecular epidemiology of *Candida albicans* and its closely related yeasts *Candida dubliniensis* and *Candida africana*. *J Clin Microbiol* 2009;47:212-4.
10. Afsarian MH, Badali H, Shokohi T, Multilocus Sequence Typing: a Molecular Typing Method with High Discriminatory Power for Identification of *Candida albicans* Strains in Epidemiological Studies. *J Mazand Univ Med Sci* 2013;23:161-74.
11. Shokohi T, Bandalizadeh Z, Hedayati MT, Mayahi S. In vitro antifungal susceptibility of *Candida* species isolated from oropharyngeal lesions of patients with cancer to some antifungal agents. *Jundishapur J Microbiol* 2011;4:S19-26.
12. Levallois J, Nadeau-Fredette A-C, Labbé A-C, Laverdière M, Ouimet D, Vallée M. Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center. *Int J Infect Dis* 2012;16:e41-e3.
13. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. M27-A3. Wayne: CLSI; 2008. (Accessed March 6, 2016, at http://shop.clsi.org/site/Sample_pdf/M27A3_sample.pdf).
14. Saranya S, Moorthy K, Malar S, Punitha T, Vinodhini R, Bhuvaneshwari M, et al. Prevalence and antifungal susceptibility pattern of *Candida albicans* from low socio-economic group. *Int J Pharm Pharmaceutical Sci* 2014;6:158-62.
15. Fesharaki SH, Haghani I, Mousavi B, Kargar ML, Boroumand M, Anvari MS, et al. Endocarditis due to a co-infection of *Candida albicans* and *Candida tropicalis* in a drug abuser. *J Med Microb* 2013;62:1763-7.
16. Laal Kargar M, Fooladi-Rad S, Mohammad Davoudi M, Khalilzadeh S, Hassanzad M, Mayahi S, et al. Fungal Colonization in Patients with Cystic Fibrosis. *J Mazand Univ Med Sci* 2013;23:204-18.
17. Kumar S, Vyas A, Kumar M, Mehra S. Application of chromagar *Candida* for identification of clinically important *Candida* species and their antifungal susceptibility pattern. *Int J Biol Med Res* 2013;4:3600-6.
18. Arendrup M, Dzajic E, Jensen R, Johansen HK, Kjaeldgaard P, Knudsen JD, et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. *Clin Microbiol Infect* 2013;19:E343-53.
19. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011): Application of new CLSI clinical breakpoints and epidemiological cutoff values to

- characterize geographic and temporal trends of antifungal resistance. *J Clin Microbiol* 2013;51:2571-81.
20. Wiebusch L, Lonchiati D, Rodrigues L, Dantas C, Almeida A, Oliveira K. Profile susceptibility to fluconazole and voriconazole antifungals by species of *Candida albicans* isolated from urine culture. *BMC Proc* 2014;8:P34.
 21. Njunda AL, Nsagha DS, Assob JC, Kamga HL, Teyim P. In vitro antifungal susceptibility patterns of *Candida albicans* from HIV and AIDS patients attending the Nylon Health District Hospital in Douala, Cameroon. *J Public Health Africa* 2012;3:2.
 22. Wabe NT, Hussein J, Suleman S, Abdella K. In vitro antifungal susceptibility of *Candida albicans* isolates from oral cavities of patients infected with human immunodeficiency virus in Ethiopia. *Retrovirology* 2012;9:P44.
 23. Roy R, Sharma G, Barman S, Chanda S. Trend of *Candida* infection and antifungal resistance in a tertiary care hospital of north east India. *Blood* 2013;100:19.
 24. Al-mamari A, Al-buryhi M, Al-heggami MA, Al-hag S. Identify and sensitivity to antifungal drugs of *Candida* species causing vaginitis isolated from vulvovaginal infected patients in Sana'a city. *Der Pharma Chemica* 2014;6:336-42.
 25. Aher CS. Species distribution, virulence factors and antifungal susceptibility profile of *Candida* isolated from Oropharyngeal lesions of HIV infected patients. *Int J Curr Microbiol App Sci* 2014;3:453-60.
 26. Awari A. Species distribution and antifungal susceptibility profile of *Candida* isolated from urine samples. *Int J App Basic Med Res.* 2011;18:228-34.
 27. Zhang L, Zhou S, Pan A, Li J, Liu B. Surveillance of antifungal susceptibilities in clinical isolates of *Candida* species at 36 hospitals in China from 2009 to 2013. *Int J Infect Dis* 2015;33:1-4.
 28. Yazdanparast SA, Khodavaisy S, Fakhim H, Shokohi T, Haghani I, Nabili M, et al. Molecular Characterization of Highly Susceptible *Candida africana* from Vulvovaginal Candidiasis. *Mycopathologia* 2015;180:317-23.